• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

射频消融治疗甲状腺 Bethesda III 结节:初步结果。

Radiofrequency ablation for thyroid Bethesda III nodules: preliminary results.

机构信息

Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Thyroid Head and Neck Ablation Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan.

出版信息

Eur Thyroid J. 2023 Oct 9;12(6). doi: 10.1530/ETJ-23-0105. Print 2023 Dec 1.

DOI:10.1530/ETJ-23-0105
PMID:37855419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10563608/
Abstract

PURPOSE

The purpose of this study was to evaluate the feasibility of radiofrequency ablation (RFA) for thyroid nodules with cytological atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS, Bethesda III).

MATERIALS AND METHODS

A total of 28 adults presenting with 30 initial Bethesda III nodules underwent thyroid RFA at a single medical center. Thyroid nodules with Bethesda IV or V according to the second aspiration were excluded. All RFA procedures were performed using the free-hand, 'moving-shot' technique under local anesthesia. Clinical features and demographics, RFA details, nodule volume reduction rate (VRR), and complications were analyzed.

RESULTS

The mean age of patients was 47.6 years, 82.1% of whom were females. Mean nodule volumes at pre-RFA, and at 6 months and 12 months post-RFA were 7.92, 2.42, and 1.25 mL, respectively, with a VRR of 77.9% at 6 months, and 87.4% at 12 months. Post-RFA complications were noted in two patients, one with transient vocal cord palsy and another with isthmus minor rupture.

CONCLUSION

RFA may be another safe alternative except for active surveillance or surgical excision for AUS/FLUS nodules with low-suspicion Thyroid Imaging Reporting and Data System features for patients who are unsuitable or strongly refuse surgery. Long-term results remain uncertain, thus further follow-up study is necessary.

摘要

目的

本研究旨在评估射频消融(RFA)治疗细胞学不确定意义的甲状腺滤泡性病变或滤泡性肿瘤(AUS/FLUS,BethesdaIII 级)的可行性。

材料与方法

本研究共纳入了 28 名成年人,共 30 个初始 BethesdaIII 级甲状腺结节,在一家医疗中心接受了甲状腺 RFA 治疗。根据第二次抽吸结果为 BethesdaIV 或 V 级的结节被排除在外。所有 RFA 手术均在局部麻醉下采用徒手、“移动射击”技术进行。分析了临床特征和人口统计学资料、RFA 细节、结节体积缩小率(VRR)和并发症。

结果

患者的平均年龄为 47.6 岁,82.1%为女性。RFA 前、6 个月和 12 个月时的平均结节体积分别为 7.92、2.42 和 1.25mL,6 个月时的 VRR 为 77.9%,12 个月时为 87.4%。两名患者在 RFA 后出现并发症,一名患者出现短暂性声带麻痹,另一名患者出现峡部小裂伤。

结论

对于低可疑性甲状腺影像报告和数据系统特征的 AUS/FLUS 结节,如果患者不适合手术或强烈拒绝手术,RFA 可能是一种安全的替代治疗方法,除了主动监测或手术切除。长期结果尚不确定,因此需要进一步的随访研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/10563608/c3cd3409f0d2/ETJ-23-0105fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/10563608/04a2574ffce6/ETJ-23-0105fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/10563608/c3cd3409f0d2/ETJ-23-0105fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/10563608/04a2574ffce6/ETJ-23-0105fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5b0/10563608/c3cd3409f0d2/ETJ-23-0105fig2.jpg

相似文献

1
Radiofrequency ablation for thyroid Bethesda III nodules: preliminary results.射频消融治疗甲状腺 Bethesda III 结节:初步结果。
Eur Thyroid J. 2023 Oct 9;12(6). doi: 10.1530/ETJ-23-0105. Print 2023 Dec 1.
2
Radiofrequency ablation is an effective treatment for Bethesda III thyroid nodules without genetic alterations.射频消融术是治疗无基因突变的 Bethesda III 甲状腺结节的有效方法。
Eur Thyroid J. 2024 May 13;13(3). doi: 10.1530/ETJ-24-0020. Print 2024 Jun 1.
3
Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.具有非典型性或意义未明的滤泡性病变的甲状腺结节(贝塞斯达Ⅲ类):超声检查和细胞学亚类的重要性
Thyroid. 2014 Jul;24(7):1115-20. doi: 10.1089/thy.2013.0650. Epub 2014 May 9.
4
Volume reduction rate of radiofrequency ablation in ≤ 2 cm Bethesda IV thyroid nodules.射频消融治疗≤2cm 美国甲状腺协会 IV 类甲状腺结节的体积缩减率。
Eur Radiol. 2024 Mar;34(3):1597-1604. doi: 10.1007/s00330-023-10185-2. Epub 2023 Sep 4.
5
Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology.在甲状腺细胞病理学报告的 Bethesda 系统中,对于诊断不明确或意义不明确的非典型性甲状腺结节,核心针活检比重复细针抽吸更有用。
Thyroid. 2012 May;22(5):468-75. doi: 10.1089/thy.2011.0185. Epub 2012 Feb 3.
6
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).甲状腺结节分类为贝塞斯达Ⅲ类(不典型/意义未明的滤泡性病变)的恶性率。
Thyroid. 2014 May;24(5):832-9. doi: 10.1089/thy.2013.0317. Epub 2014 Mar 10.
7
Approach to Bethesda system category III thyroid nodules according to US-risk stratification.根据美国风险分层,贝塞斯达系统类别 III 甲状腺结节的处理方法。
Endocr J. 2022 Jan 28;69(1):67-74. doi: 10.1507/endocrj.EJ21-0300. Epub 2021 Aug 18.
8
ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.ACR TI-RADS 与 ATA US 评分有助于对具有不确定细胞学特征的甲状腺结节进行管理。
BMC Endocr Disord. 2019 Oct 29;19(1):112. doi: 10.1186/s12902-019-0429-5.
9
Risk Stratification of Thyroid Nodules With Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cytology Using Ultrasonography Patterns Defined by the 2015 ATA Guidelines.使用2015年美国甲状腺协会(ATA)指南定义的超声模式对具有意义不明确的非典型性/意义不明确的滤泡性病变(AUS/FLUS)细胞学特征的甲状腺结节进行风险分层。
Ann Otol Rhinol Laryngol. 2017 Sep;126(9):625-633. doi: 10.1177/0003489417719472. Epub 2017 Jul 18.
10
Risk factors associated with malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS/FLUS).与甲状腺结节恶性肿瘤以及分类为贝塞斯达III类(AUS/FLUS)的手术分诊相关的风险因素。
Eur J Surg Oncol. 2016 Jan;42(1):87-93. doi: 10.1016/j.ejso.2015.09.026. Epub 2015 Oct 19.

引用本文的文献

1
Efficacy and safety of thermal ablation for Bethesda III/IV thyroid nodules: a retrospective study.热消融治疗贝塞斯达III/IV类甲状腺结节的疗效与安全性:一项回顾性研究
Front Endocrinol (Lausanne). 2025 May 2;16:1572535. doi: 10.3389/fendo.2025.1572535. eCollection 2025.
2
Safety and Feasibility of US-guided Microwave Ablation for the Treatment of Bethesda III Thyroid Nodules with Negative Eight-Gene Panel Mutational Profile.超声引导下微波消融治疗八基因panel突变谱阴性的贝塞斯达Ⅲ类甲状腺结节的安全性和可行性
Radiol Imaging Cancer. 2025 Jan;7(1):e240058. doi: 10.1148/rycan.240058.
3
Thermal ablation for Bethesda III and IV thyroid nodules: current diagnosis and management.

本文引用的文献

1
2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation.2022年台湾甲状腺射频消融临床多中心专家共识与建议
Ultrasonography. 2023 Jul;42(3):357-375. doi: 10.14366/usg.22126. Epub 2022 Nov 19.
2
Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.评估用于不确定甲状腺结节的分子诊断检测的临床验证研究的偏倚和局限性:系统评价和荟萃分析。
Thyroid. 2022 Oct;32(10):1144-1157. doi: 10.1089/thy.2022.0269. Epub 2022 Sep 26.
3
Correlation Between Ultrasound and Cytological Findings of Patients With Suspicious Thyroid Nodules: The King Hamad University Hospital Experience.
贝塞斯达Ⅲ级和Ⅳ级甲状腺结节的热消融:当前的诊断与管理
Ultrasonography. 2024 Nov;43(6):395-406. doi: 10.14366/usg.24083. Epub 2024 Aug 5.
4
Radiofrequency ablation is an effective treatment for Bethesda III thyroid nodules without genetic alterations.射频消融术是治疗无基因突变的 Bethesda III 甲状腺结节的有效方法。
Eur Thyroid J. 2024 May 13;13(3). doi: 10.1530/ETJ-24-0020. Print 2024 Jun 1.
甲状腺可疑结节患者超声与细胞学检查结果的相关性:哈马德国王大学医院的经验
Cureus. 2022 Mar 5;14(3):e22877. doi: 10.7759/cureus.22877. eCollection 2022 Mar.
4
Ultrasonography and Fine-Needle Aspiration in Indeterminate Thyroid Nodules: A Systematic Review of Diagnostic Test Accuracy.超声检查和细针抽吸在甲状腺结节诊断中的应用:诊断试验准确性的系统评价。
Laryngoscope. 2022 Jan;132(1):242-251. doi: 10.1002/lary.29778. Epub 2021 Aug 19.
5
Radiofrequency ablation for treatment of thyroid follicular neoplasm with low SUV in PET/CT study.射频消融治疗 PET/CT 研究中 SUV 值低的甲状腺滤泡性肿瘤。
Int J Hyperthermia. 2021;38(1):963-969. doi: 10.1080/02656736.2021.1912414.
6
Efficacy and safety of single-session radiofrequency ablation for benign thyroid nodules of different sizes: a retrospective study.单次射频消融治疗不同大小良性甲状腺结节的疗效和安全性:一项回顾性研究。
Int J Hyperthermia. 2020;37(1):1082-1089. doi: 10.1080/02656736.2020.1782485.
7
2020 European Thyroid Association Clinical Practice Guideline for the Use of Image-Guided Ablation in Benign Thyroid Nodules.2020年欧洲甲状腺协会关于影像引导下良性甲状腺结节消融治疗的临床实践指南。
Eur Thyroid J. 2020 Jul;9(4):172-185. doi: 10.1159/000508484. Epub 2020 Jun 8.
8
Impact of Molecular Testing on the Management of Indeterminate Thyroid Nodules Among Western and Asian Countries: a Systematic Review and Meta-analysis.分子检测对西方国家和亚洲国家甲状腺结节性质不明患者管理的影响:系统评价和荟萃分析。
Endocr Pathol. 2021 Jun;32(2):269-279. doi: 10.1007/s12022-020-09643-0. Epub 2020 Aug 7.
9
Evaluation of the Bethesda System and the ACR TIRADS in an Endemic Goiter Region.评估在地方性甲状腺肿地区的 Bethesda 系统和 ACR TIRADS。
Endocr Res. 2020 Nov;45(4):226-232. doi: 10.1080/07435800.2020.1799226. Epub 2020 Jul 30.
10
Accuracy of thyroid imaging reporting and data system category 4 or 5 for diagnosing malignancy: a systematic review and meta-analysis.甲状腺影像报告和数据系统分类 4 或 5 用于诊断恶性肿瘤的准确性:系统评价和荟萃分析。
Eur Radiol. 2020 Oct;30(10):5611-5624. doi: 10.1007/s00330-020-06875-w. Epub 2020 Apr 30.